Top

CardioVascular and Interventional Radiology

Published in:

01-10-2012 | Clinical Investigation

Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis

Authors: Katerina Malagari, Mary Pomoni, Hippocrates Moschouris, Evanthia Bouma, John Koskinas, Aspasia Stefaniotou, Athanasios Marinis, Alexios Kelekis, Efthymia Alexopoulou, Achilles Chatziioannou, Katerina Chatzimichael, Spyridon Dourakis, Nikolaos Kelekis, Spyros Rizos, Dimitrios Kelekis

Published in: CardioVascular and Interventional Radiology | Issue 5/2012

Abstract

Purpose

The purpose of this study was to report on the 5-year survival of hepatocellular carcinoma (HCC) patients treated with DC Bead loaded with doxorubicin (DEB-DOX) in a scheduled scheme in up to three treatments and thereafter on demand.

Materials and Methods

173 HCC patients not suitable for curable treatments were prospectively enrolled (mean age 70.4 ± 7.4 years). Child-Pugh (Child) class was A/B (102/71 [59/41 %]), Okuda stage was 0/1/2 (91/61/19 [53.2/35.7/11.1 %]), and mean lesion diameter was 7.6 ± 2.1 cm. Lesion morphology was one dominant ≤5 cm (22 %), one dominant >5 cm (41.6 %), multifocal ≤5 (26 %), and multifocal >5 (10.4 %).

Results

Overall survival at 1, 2, 3, 4, and 5 years was 93.6, 83.8, 62, 41.04, and 22.5 %, with higher rates achieved in Child class A compared with Child class B patients (95, 88.2, 61.7, 45, and 29.4 % vs. 91.5, 75, 50.7, 35.2, and 12.8 %). Mean overall survival was 43.8 months (range 1.2–64.8). Cumulative survival was better for Child class A compared with Child class B patients (p = 0.029). For patients with dominant lesions ≤5 cm 1-, 2-, 3-, 4-, and 5-year survival rates were 100, 95.2, 71.4, 66.6, and 47.6 % for Child class A and 94.1, 88.2, 58.8, 41.2, 29.4, and 23.5 % for Child class B patients. Regarding DEB-DOX treatment, multivariate analysis identified number of lesions (p = 0.033), lesion vascularity (p < 0.0001), initially achieved complete response (p < 0.0001), and objective response (p = 0.046) as significant and independent determinants of 5-year survival.

Conclusion

DEB-DOX results, with high rates of 5-year survival for patients, not amenable to curative treatments. Number of lesions, lesion vascularity, and local response were significant independent determinants of 5-year survival.

Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164–1171PubMedCrossRef

Llovet JM, Real MI, Montana X et al (2002) Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359(9319):1734–1739PubMedCrossRef

Lammer J, Malagari K, Vogl T et al (2010) PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCrossRef

Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481PubMedCrossRef

Poon RN, Tso WK, Pang RWC et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5(9):1100–1108PubMedCrossRef

Kettenbach J, Stadler A, Katzler I et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31(3):468–476PubMedCrossRef

Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolisation of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB)” Results of an open label study of 62 patients. Cardiovasc Intervent Radiol 31(2):269–280PubMedCrossRef

Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead^TM. Abdom Imaging 33(5):512–519PubMedCrossRef

Reyes DK, Vossen JA, Kamel IR et al (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15(6):526–532PubMedCrossRef

10.

Poggi G, Quaretti P, Minoia C et al (2008) Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28(6B):3835–3842PubMed

11.

Biondi M, Fusco S, Lewis AL et al (2012) New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead™ for use in transarterial chemoembolization (TACE). J Biomater Sci Polym Ed 23(1–4):333–354PubMedCrossRef

12.

Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC Bead(™): results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34(4):774–785PubMedCrossRef

13.

National Cancer Institute (2003) Common Terminology Criteria for Adverse Events, version 3.0. National Cancer Institute, Bethesda, Maryland

14.

Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (2003) Notice of Modifications March 31, 2003–June 10, 2003

15.

Bruix J, Sherman M, Llovet JM et al (2001) EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef

16.

Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30(1):6–25PubMedCrossRef

17.

Vogl TJ, Naguib NN, Nour-Eldin NE et al (2009) Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 72(3):116–505

18.

Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664):614–616PubMedCrossRef

19.

Raoul JL, Sangro B, Forner A et al (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37(3):212–220PubMedCrossRef

20.

O’Suilleabhain CB, Poon RTP, Yong JL et al (2003) Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90(3):325–331PubMedCrossRef

21.

Takayasu K, Arii S, Ikai I et al (2006) Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131(2):461–469PubMedCrossRef

22.

Maeda S, Fujiyama S, Tanaka M et al (2002) Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 23(3):202–210PubMedCrossRef

23.

Hayashi K, Ina H, Tezuka M et al (2007) Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc Intervent Radiol 30(6):1144–1155PubMedCrossRef

24.

Lencioni R, Cioni D, Crocetti L et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961–967PubMedCrossRef

25.

Montorsi M, Santambrogio R, Bianchi P et al (2005) Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg 9(1):62–68PubMedCrossRef

26.

Omata M, Tateishi R, Yoshida H et al (2004) Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 127(5 Suppl 1):159–166CrossRef

27.

Lam VW, Ng KK, Chok KS et al (2008) Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 207(1):20–29PubMedCrossRef

28.

Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 19(10):1490–1496PubMedCrossRef

29.

Burrel M, Reig M, Forner A, et al. (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DC Beads. Implications for clinical practice and trial design. J Hepatol. doi:10.1016/j.jhep.2012.01.008

30.

Lee JK, Chung YH, Song BC et al (2002) Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 17(1):52–58PubMedCrossRef

31.

Grieco A, Marcoccia S, Miele L et al (2003) Transarterial hemoembolisation (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 50(49):207–212PubMed

32.

Memon K, Kulik L, Lewandowski RJ et al (2011) Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141(2):526–535PubMedCrossRef

33.

Kwok PC, Lam TW, Chan SC et al (2000) A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 32(6):955–964PubMedCrossRef

34.

Ernst O, Sergent G, Mizrahi D et al (1999) Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 172(1):59–64PubMed

35.

Herber SC, Otto G, Schneider J et al (2008) Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol 190(4):1035–1042PubMedCrossRef

36.

Venook AP, Stagg RJ, Lewis BJ et al (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8(6):1108–1114PubMed

37.

Lencioni R, De Baere Th, Burrel M, et al. (2011) Transcatheter treatment of hepatocellular carcinoma with doxorubicin loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. doi:10.1007/s00270-011-0287-7

38.

Brown DB, Nikolic B, Covey AM et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287–294PubMedCrossRef

Title: Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis
Authors: Katerina Malagari
Mary Pomoni
Hippocrates Moschouris
Evanthia Bouma
John Koskinas
Aspasia Stefaniotou
Athanasios Marinis
Alexios Kelekis
Efthymia Alexopoulou
Achilles Chatziioannou
Katerina Chatzimichael
Spyridon Dourakis
Nikolaos Kelekis
Spyros Rizos
Dimitrios Kelekis
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 5/2012
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-012-0394-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis

Abstract

Purpose

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Early Results with the Use of Heparin-bonded Stent Graft to Rescue Failed Angioplasty of Chronic Femoropopliteal Occlusive Lesions: TASC D Lesions Have a Poor Outcome

Hepatocellular Carcinoma Complicated by Gastroduodenal Obstruction: Palliative Treatment with Metallic Stent Placement

CT-Guided Percutaneous Biopsy of a Mass Lesion in the Upper Presacral Space: A Sacral Transneuroforaminal Approach

Successful Recanalization of a Longstanding Right Common Iliac Artery Occlusion with a Radiofrequency Guidewire

Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery

Endovascular Management of the Arteria Profunda Femoralis: Long-Term Angiographic and Clinical Outcomes